曲坦类药物：现状。

Triptans: where things stand.

机构信息

Thomas Jefferson University, 111 South 11th Street, Suite 8130, Philadelphia, PA, 19107, USA.

出版信息

Curr Treat Options Neurol. 2010 Sep;12(5):454-63. doi: 10.1007/s11940-010-0082-9.

DOI:10.1007/s11940-010-0082-9

PMID:20842600

Abstract

Triptans, selective serotonin receptor agonists, were developed almost 20 years ago and represented a major breakthrough in the treatment of acute migraine attacks. Since then, the triptans have become first-line agents for most patients with migraine, both with and without aura, unless contraindicated. This article reviews the development of triptans, discusses reasons for their success or failure, and examines the limitations and controversies surrounding this class of medication.

摘要

曲坦类药物（选择性 5-羟色胺受体激动剂）于近 20 年前问世，是治疗急性偏头痛发作的重大突破。自此以后，曲坦类药物已成为大多数有或无先兆偏头痛患者的一线治疗药物，除非禁忌，否则首选此类药物。本文回顾了曲坦类药物的发展历程，讨论了其成败的原因，并研究了该类药物的局限性和争议。